Skip to main content

LEAD Grants for European Patient Groups

Patient organizations have until February 18 to apply for CSL Behring’s Local Empowerment for Advocacy Development (LEAD) Grants. The program, in its fifth year, helps patient advocates advance their vital work.

Scattering of letters with the word LEAD in the center

When they have the resources they need, patient advocacy groups can accelerate positive change for the rare disease community. CSL Behring’s LEAD Grant Program in Europe, now accepting applications, helps patient organizations fund key projects.

LEAD stands for Local Empowerment for Advocacy Development and the program offers up to €10,000 for each selected European advocacy organization.

Here’s how two of last year’s recipients used the funds: The Czech Society of Haemophilia raised awareness about women and bleeding disorders in support of early diagnosis and optimal care. Associazione Immunodeficienze Primitive, a patient organization in Italy, advocated for increased plasma and blood collection and for newborn screening that identifies primary immunodeficiency diseases.

"Through the LEAD Grant, we empower grassroots advocacy, transforming health care for those facing rare diseases,” said Lutz Bonacker, Senior Vice President and General Manager, CSL Behring Europe.

Applications for the European grants are due by February 18. Learn more about how to apply.

CSL Behring, a business unit of CSL, develops and manufactures medicines for people who have rare and serious diseases, such as bleeding disorders, primary immunodeficiencies, chronic inflammatory demyelinating polyneuropathy (CIDP), hereditary angioedema (HAE) and Alpha 1 Antitrypsin Deficiency.

CSL Behring also provides LEAD Grants for U.S. patient organizations and accepts applications in October.